JATT III Acquisition Corp Ordinary Shares

JATT III Acquisition Corp Ordinary Shares(JTTT)股票分析

$10.300

0.000 (0.00%)收盤時

Loading chart…
最高
10.320
開盤
10.250
成交量加權均價
10.28
成交量
5.85K
市值
—
最低
10.213
成交金額
60.10K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

JATT III Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any business combination target, and the Company has not initiated any substantive discussions, directly or indirectly, with any business combination target. The Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. The Company is not engaged in any business operations and has not generated any revenue.

AI 分析 of JATT III Acquisition Corp Ordinary Shares (JTTT)

持有

JTTT is not a strong buy right now due to its low RSI of 37.401, indicating potential oversold conditions, and a current price of 10.30, which is close to its 52-week low of 10.00. The stock has shown a 20-day change of -4.63%, suggesting a downward trend. However, the projected final change of +1047.66% based on historical patterns indicates potential for significant upside in the long term. The main risk is its current ratio of 0.28, indicating liquidity concerns.

估值指標

JATT III Acquisition Corp Ordinary Shares(JTTT)目前預期本益比為 0.00,5 年平均預期本益比為 。

預期本益比

5 年均值 P/E
目前P/E
0.00

預期 EV/EBITDA

5 年均值 EV/EBITDA
目前EV/EBITDA
0.00

預期股價營收比

5 年均值 P/S
目前P/S
0.00

事件時間軸

2026-09-21 (ET)

16:00:00

Nscale Limited Files for IPO, Plans to List on NYSE

JTTT 常見問題 —— 由 Alphio AI 解答

JATT III Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any business combination target, and the Company has not initiated any substantive discussions, directly or indirectly, with any business combination target. The Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. The Company is not engaged in any business operations and has not generated any revenue.

JTTT is not a strong buy right now due to its low RSI of 37.401, indicating potential oversold conditions, and a current price of 10.30, which is close to its 52-week low of 10.00. The stock has shown a 20-day change of -4.63%, suggesting a downward trend. However, the projected final change of +1047.66% based on historical patterns indicates potential for significant upside in the long term. The main risk is its current ratio of 0.28, indicating liquidity concerns.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易